Allosteric Integrase Inhibitors
- Authors: Victoria Hann1, Peter Dawson2, Mark Ashton3
-
View Affiliations Hide Affiliations1 Department of Pharmacy, Health and Wellbeing, University of Sunderland, Sunderland, Tyne and Wear, UK 2 Department of Pharmacy, Health and Wellbeing, University of Sunderland, Sunderland, Tyne and Wear, UK 3 Department of Pharmacy, Health and Wellbeing, University of Sunderland, Sunderland, Tyne and Wear, UK
- Source: Frontiers in Clinical Drug Research - HIV: Volume 3 , pp 49-126
- Publication Date: December 2016
- Language: English
Preview this chapter:
Allosteric Integrase Inhibitors, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9781681082295/chapter-2-1.gif
In the recent years, integrase (IN) has emerged as an important new target for the development of anti-HIV-1 agents. The enzyme is involved in a key stage of the retroviral replicative cycle, and interacts with a range of cellular co-factors. Due to the absolute necessity of the enzyme for successful infection and the range of cellular cofactors employed by the enzyme, new ways of targeting both IN and its cofactors could yield agents with improved resistance profiles. Allosteric inhibitors are currently receiving a great deal of focus from both academia and industry alike and offer the possibility of a new class of anti-HIV-1 inhibitor.
Hardbound ISBN:
9781681082301
Ebook ISBN:
9781681082295
-
From This Site
/content/books/9781681082295.chapter-2dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
/content/books/9781681082295.chapter-2
dcterms_subject,pub_keyword
-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData
10
5
Chapter
content/books/9781681082295
Book
false
en
